Identification

Name
Cerivastatin
Accession Number
DB00439  (APRD00102)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Cerivastatin sodium6Q18G1060S143201-11-0GPUADMRJQVPIAS-ASTDGNLGSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BaycolTablet0.4 mgOralBayer2000-01-062001-10-26Canada
BaycolTablet0.8 mgOralBayer2000-12-282001-10-26Canada
Baycol (0.2mg)Tablet0.2 mgOralBayer1998-03-112001-10-26Canada
Baycol (0.3mg)Tablet0.3 mgOralBayer1998-03-112001-10-26Canada
International/Other Brands
Lipobay / Rivastatin
Categories
UNII
AM91H2KS67
CAS number
145599-86-6
Weight
Average: 459.5503
Monoisotopic: 459.242101408
Chemical Formula
C26H34FNO5
InChI Key
SEERZIQQUAZTOL-ANMDKAQQSA-N
InChI
InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1
IUPAC Name
(3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
SMILES
COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C

Pharmacology

Indication

Used as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate.

Pharmacodynamics

Cerivastatin, a competitive HMG-CoA reductase inhibitor effective in lowering LDL cholesterol and triglycerides, is used to treat primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb).

Mechanism of action

Cerivastatin competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the hepatic enzyme responsible for converting HMG-CoA to mevalonate. As mevalonate is a precursor of sterols such as cholesterol, this results in a decrease in cholesterol in hepatic cells, upregulation of LDL-receptors, and an increase in hepatic uptake of LDL-cholesterol from the circulation.

TargetActionsOrganism
A3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor
Human
Absorption

The mean absolute oral bioavailability 60% (range 39 - 101%).

Volume of distribution
Not Available
Protein binding

More than 99% of the circulating drug is bound to plasma proteins (80% to albumin).

Metabolism

Hepatic. Biotransformation pathways for cerivastatin in humans include the following: demethylation of the benzylic methyl ether to form Ml and hydroxylation of the methyl group in the 6'-isopropyl moiety to form M23.

Route of elimination
Not Available
Half life

2-3 hours

Clearance
Not Available
Toxicity

Rhabdomyolysis, liver concerns

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Cerivastatin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
6-Deoxyerythronolide BThe risk or severity of rhabdomyolysis can be increased when 6-Deoxyerythronolide B is combined with Cerivastatin.Experimental
AbirateroneThe serum concentration of Cerivastatin can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Cerivastatin can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe serum concentration of Cerivastatin can be increased when it is combined with Acetazolamide.Approved, Vet Approved
Acetyl sulfisoxazoleThe serum concentration of Cerivastatin can be increased when it is combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Cerivastatin.Approved, Investigational
AldesleukinThe serum concentration of Cerivastatin can be increased when it is combined with Aldesleukin.Approved
AlmasilateThe serum concentration of Cerivastatin can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Cerivastatin can be decreased when it is combined with Aloglutamol.Approved
AlprazolamThe serum concentration of Cerivastatin can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AluminiumThe serum concentration of Cerivastatin can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Cerivastatin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Cerivastatin can be decreased when it is combined with Aluminium glycinate.Experimental
AmbroxolThe serum concentration of Cerivastatin can be increased when it is combined with Ambroxol.Approved, Investigational
AmiodaroneThe serum concentration of Cerivastatin can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Cerivastatin can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Cerivastatin.Approved, Investigational
Amphotericin BThe risk or severity of rhabdomyolysis can be increased when Amphotericin B is combined with Cerivastatin.Approved, Investigational
AmprenavirThe serum concentration of Cerivastatin can be increased when it is combined with Amprenavir.Approved, Investigational
AntipyrineThe serum concentration of Cerivastatin can be increased when it is combined with Antipyrine.Approved, Investigational
ApalutamideThe serum concentration of Cerivastatin can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Cerivastatin can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Cerivastatin.Approved, Investigational
Arsenic trioxideThe serum concentration of Cerivastatin can be increased when it is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Cerivastatin can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Cerivastatin can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe risk or severity of rhabdomyolysis can be increased when Atazanavir is combined with Cerivastatin.Approved, Investigational
AtomoxetineThe serum concentration of Cerivastatin can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Cerivastatin is combined with Atorvastatin.Approved
AVE9633The risk or severity of rhabdomyolysis can be increased when AVE9633 is combined with Cerivastatin.Investigational
AzelastineThe serum concentration of Cerivastatin can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Cerivastatin can be increased when it is combined with Azithromycin.Approved
Benzyl alcoholThe serum concentration of Cerivastatin can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Cerivastatin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Cerivastatin can be increased when it is combined with Betamethasone.Approved, Vet Approved
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Cerivastatin.Approved, Investigational
BicalutamideThe serum concentration of Cerivastatin can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe serum concentration of Cerivastatin can be increased when it is combined with Bifonazole.Approved, Investigational
Bismuth subcitrate potassiumThe serum concentration of Cerivastatin can be decreased when it is combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe serum concentration of Cerivastatin can be decreased when it is combined with Bismuth subnitrate.Approved
BoceprevirThe serum concentration of Cerivastatin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Cerivastatin can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Cerivastatin can be increased when combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cerivastatin.Approved
Brefeldin AThe risk or severity of rhabdomyolysis can be increased when Brefeldin A is combined with Cerivastatin.Experimental
Brentuximab vedotinThe serum concentration of Cerivastatin can be increased when it is combined with Brentuximab vedotin.Approved, Investigational
BromocriptineThe serum concentration of Cerivastatin can be increased when it is combined with Bromocriptine.Approved, Investigational
Bryostatin 1The risk or severity of rhabdomyolysis can be increased when Bryostatin 1 is combined with Cerivastatin.Investigational
BuprenorphineThe serum concentration of Cerivastatin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
CabergolineThe serum concentration of Cerivastatin can be increased when it is combined with Cabergoline.Approved
CaffeineThe serum concentration of Cerivastatin can be increased when it is combined with Caffeine.Approved
Calcium silicateThe serum concentration of Cerivastatin can be decreased when it is combined with Calcium silicate.Experimental
CandicidinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Cerivastatin.Withdrawn
CapsaicinThe serum concentration of Cerivastatin can be increased when it is combined with Capsaicin.Approved
CarbamazepineThe serum concentration of Cerivastatin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbomycinThe risk or severity of rhabdomyolysis can be increased when Carbomycin is combined with Cerivastatin.Vet Approved
CarvedilolThe serum concentration of Cerivastatin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Cerivastatin can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Cerivastatin can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Cerivastatin can be increased when it is combined with Ceritinib.Approved
CethromycinThe risk or severity of rhabdomyolysis can be increased when Cethromycin is combined with Cerivastatin.Investigational
ChloramphenicolThe serum concentration of Cerivastatin can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Cerivastatin can be increased when it is combined with Chlorzoxazone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Cerivastatin.Approved, Investigational
CimetidineThe serum concentration of Cerivastatin can be increased when it is combined with Cimetidine.Approved, Investigational
Cimicifuga racemosaThe serum concentration of Cerivastatin can be increased when it is combined with Cimicifuga racemosa.Approved, Experimental
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofibrate is combined with Cerivastatin.Approved, Investigational
CiprofloxacinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ciprofloxacin is combined with Cerivastatin.Approved, Investigational
CisaprideThe serum concentration of Cerivastatin can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Cerivastatin can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of Cerivastatin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Cerivastatin can be increased when it is combined with Clomifene.Approved, Investigational
ClopidogrelThe risk or severity of rhabdomyolysis can be increased when Clopidogrel is combined with Cerivastatin.Approved
ClotiazepamThe serum concentration of Cerivastatin can be increased when it is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Cerivastatin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Cerivastatin can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Cerivastatin can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Cerivastatin can be increased when it is combined with Cocaine.Approved, Illicit
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Cerivastatin.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Coltuximab ravtansineThe risk or severity of rhabdomyolysis can be increased when Coltuximab ravtansine is combined with Cerivastatin.Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Cerivastatin.Approved, Investigational
Cortisone acetateThe serum concentration of Cerivastatin can be increased when it is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Cerivastatin can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe serum concentration of Cerivastatin can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Cerivastatin can be increased when it is combined with Curcumin.Approved, Investigational
CyclophosphamideThe serum concentration of Cerivastatin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cerivastatin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Cerivastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Cerivastatin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Cerivastatin can be increased when it is combined with Daclatasvir.Approved, Investigational
DalfopristinThe serum concentration of Cerivastatin can be increased when it is combined with Dalfopristin.Approved
DanazolThe risk or severity of myopathy and rhabdomyolysis can be increased when Danazol is combined with Cerivastatin.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Cerivastatin is combined with Daptomycin.Approved, Investigational
DarunavirThe serum concentration of Cerivastatin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Cerivastatin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Cerivastatin can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Cerivastatin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Cerivastatin can be increased when it is combined with Delavirdine.Approved
DesipramineThe serum concentration of Cerivastatin can be increased when it is combined with Desipramine.Approved, Investigational
DexamethasoneThe serum concentration of Cerivastatin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexniguldipineThe serum concentration of Cerivastatin can be increased when it is combined with Dexniguldipine.Experimental
DextropropoxypheneThe serum concentration of Cerivastatin can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe serum concentration of Cerivastatin can be increased when it is combined with Dexverapamil.Experimental
DiazepamThe serum concentration of Cerivastatin can be increased when it is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe excretion of Cerivastatin can be decreased when combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Cerivastatin can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cerivastatin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cerivastatin.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Cerivastatin.Experimental
DihydroergotamineThe serum concentration of Cerivastatin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Cerivastatin can be decreased when combined with Diltiazem.Approved, Investigational
Dimethyl sulfoxideThe serum concentration of Cerivastatin can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DirithromycinThe risk or severity of rhabdomyolysis can be increased when Dirithromycin is combined with Cerivastatin.Approved, Investigational
DocetaxelThe serum concentration of Cerivastatin can be increased when it is combined with Docetaxel.Approved, Investigational
DoramectinThe risk or severity of rhabdomyolysis can be increased when Doramectin is combined with Cerivastatin.Vet Approved
DoxazosinThe serum concentration of Cerivastatin can be increased when it is combined with Doxazosin.Approved
DoxorubicinThe serum concentration of Cerivastatin can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Cerivastatin can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Cerivastatin can be increased when it is combined with Dronedarone.Approved
EconazoleThe serum concentration of Cerivastatin can be increased when it is combined with Econazole.Approved
EfavirenzThe serum concentration of Cerivastatin can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Cerivastatin can be increased when it is combined with Elbasvir.Approved
EltrombopagThe serum concentration of Cerivastatin can be increased when it is combined with Eltrombopag.Approved
EmopamilThe serum concentration of Cerivastatin can be increased when it is combined with Emopamil.Experimental
EnasidenibThe serum concentration of Cerivastatin can be increased when it is combined with Enasidenib.Approved, Investigational
EnzalutamideThe serum concentration of Cerivastatin can be decreased when it is combined with Enzalutamide.Approved
EpinephrineThe serum concentration of Cerivastatin can be increased when it is combined with Epinephrine.Approved, Vet Approved
EpofolateThe risk or severity of rhabdomyolysis can be increased when Epofolate is combined with Cerivastatin.Investigational
Epothilone DThe risk or severity of rhabdomyolysis can be increased when Epothilone D is combined with Cerivastatin.Experimental, Investigational
EprinomectinThe risk or severity of rhabdomyolysis can be increased when Eprinomectin is combined with Cerivastatin.Vet Approved
ErgonovineThe serum concentration of Cerivastatin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Cerivastatin can be increased when it is combined with Ergotamine.Approved
ErlotinibThe risk or severity of adverse effects can be increased when Erlotinib is combined with Cerivastatin.Approved, Investigational
ErythromycinThe serum concentration of Cerivastatin can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EstradiolThe serum concentration of Cerivastatin can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EthanolThe risk or severity of myopathy and rhabdomyolysis can be increased when Ethanol is combined with Cerivastatin.Approved
Ethinyl EstradiolThe serum concentration of Cerivastatin can be decreased when it is combined with Ethinyl Estradiol.Approved
EtoposideThe serum concentration of Cerivastatin can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Cerivastatin can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Cerivastatin can be decreased when it is combined with Etravirine.Approved
EverolimusThe excretion of Cerivastatin can be decreased when combined with Everolimus.Approved
EzetimibeThe serum concentration of Cerivastatin can be increased when it is combined with Ezetimibe.Approved
FelodipineThe metabolism of Cerivastatin can be decreased when combined with Felodipine.Approved, Investigational
FenofibrateThe risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Cerivastatin.Approved
Fenofibric acidThe risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibric acid is combined with Cerivastatin.Approved
FentanylThe serum concentration of Cerivastatin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cerivastatin.Approved
FluconazoleThe risk or severity of adverse effects can be increased when Fluconazole is combined with Cerivastatin.Approved, Investigational
FluoxetineThe serum concentration of Cerivastatin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlurithromycinThe risk or severity of rhabdomyolysis can be increased when Flurithromycin is combined with Cerivastatin.Experimental
Fluticasone propionateThe excretion of Cerivastatin can be decreased when combined with Fluticasone propionate.Approved
FluvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Fluvastatin is combined with Cerivastatin.Approved
FluvoxamineThe serum concentration of Cerivastatin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Cerivastatin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cerivastatin can be increased when it is combined with Fosaprepitant.Approved
FosnetupitantThe serum concentration of Cerivastatin can be increased when it is combined with Fosnetupitant.Approved
FosphenytoinThe serum concentration of Cerivastatin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Cerivastatin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallopamilThe serum concentration of Cerivastatin can be increased when it is combined with Gallopamil.Investigational
GanciclovirThe risk or severity of myopathy and rhabdomyolysis can be increased when Ganciclovir is combined with Cerivastatin.Approved, Investigational
GemfibrozilThe risk or severity of rhabdomyolysis, myoglobinuria, and elevated creatine kinase (CPK) can be increased when Gemfibrozil is combined with Cerivastatin.Approved
GlyburideThe serum concentration of Cerivastatin can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Cerivastatin can be increased when it is combined with Glycerin.Approved, Investigational
Glycerol PhenylbutyrateThe serum concentration of Cerivastatin can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GPI-1485The risk or severity of rhabdomyolysis can be increased when GPI-1485 is combined with Cerivastatin.Investigational
HaloperidolThe serum concentration of Cerivastatin can be increased when it is combined with Haloperidol.Approved
HydralazineThe serum concentration of Cerivastatin can be increased when it is combined with Hydralazine.Approved
HydrotalciteThe serum concentration of Cerivastatin can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
IbandronateThe risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Cerivastatin.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Cerivastatin.Approved
IbuprofenThe serum concentration of Cerivastatin can be increased when it is combined with Ibuprofen.Approved
IdelalisibThe serum concentration of Cerivastatin can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Cerivastatin can be increased when it is combined with Ifosfamide.Approved
IloperidoneThe serum concentration of Cerivastatin can be increased when it is combined with Iloperidone.Approved
ImatinibThe serum concentration of Cerivastatin can be increased when it is combined with Imatinib.Approved
IndinavirThe serum concentration of Cerivastatin can be increased when it is combined with Indinavir.Approved
IndisulamThe serum concentration of Cerivastatin can be increased when it is combined with Indisulam.Investigational
IrbesartanThe serum concentration of Cerivastatin can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe excretion of Cerivastatin can be decreased when combined with Irinotecan.Approved, Investigational
IsavuconazoleThe serum concentration of Cerivastatin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Cerivastatin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe serum concentration of Cerivastatin can be increased when it is combined with Isoniazid.Approved, Investigational
IsradipineThe serum concentration of Cerivastatin can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Cerivastatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cerivastatin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe risk or severity of rhabdomyolysis can be increased when Ivermectin is combined with Cerivastatin.Approved, Investigational, Vet Approved
IxabepiloneThe risk or severity of rhabdomyolysis can be increased when Ixabepilone is combined with Cerivastatin.Approved, Investigational
JosamycinThe serum concentration of Cerivastatin can be increased when it is combined with Josamycin.Approved, Investigational
KetazolamThe serum concentration of Cerivastatin can be increased when it is combined with Ketazolam.Approved
KetoconazoleThe serum concentration of Cerivastatin can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of rhabdomyolysis can be increased when Kitasamycin is combined with Cerivastatin.Experimental
KOS-1584The risk or severity of rhabdomyolysis can be increased when KOS-1584 is combined with Cerivastatin.Investigational
LamivudineThe risk or severity of myopathy and rhabdomyolysis can be increased when Lamivudine is combined with Cerivastatin.Approved, Investigational
LamotrigineThe serum concentration of Cerivastatin can be decreased when it is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Cerivastatin can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Cerivastatin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibThe serum concentration of Cerivastatin can be increased when it is combined with Lapatinib.Approved, Investigational
LercanidipineThe risk or severity of myopathy and rhabdomyolysis can be increased when Lercanidipine is combined with Cerivastatin.Approved, Investigational
LevofloxacinThe serum concentration of Cerivastatin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe serum concentration of Cerivastatin can be increased when it is combined with Levosalbutamol.Approved, Investigational
LidocaineThe serum concentration of Cerivastatin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Cerivastatin can be increased when it is combined with Linagliptin.Approved
LipegfilgrastimCerivastatin may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Cerivastatin.Approved, Investigational
LomerizineThe serum concentration of Cerivastatin can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Cerivastatin can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe serum concentration of Cerivastatin can be increased when it is combined with Lomustine.Approved, Investigational
LoperamideThe serum concentration of Cerivastatin can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Cerivastatin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Cerivastatin can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Cerivastatin can be increased when it is combined with Lorpiprazole.Approved
Lorvotuzumab mertansineThe risk or severity of rhabdomyolysis can be increased when Lorvotuzumab mertansine is combined with Cerivastatin.Investigational
LosartanThe serum concentration of Cerivastatin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Cerivastatin can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Cerivastatin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Cerivastatin can be increased when it is combined with Lumacaftor.Approved
LurasidoneThe serum concentration of Cerivastatin can be increased when it is combined with Lurasidone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Cerivastatin.Illicit, Investigational, Withdrawn
MagaldrateThe serum concentration of Cerivastatin can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium oxideThe serum concentration of Cerivastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Cerivastatin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Cerivastatin can be decreased when it is combined with Magnesium silicate.Approved
MefloquineThe serum concentration of Cerivastatin can be increased when it is combined with Mefloquine.Approved, Investigational
MepartricinThe risk or severity of rhabdomyolysis can be increased when Mepartricin is combined with Cerivastatin.Experimental
MequitazineThe serum concentration of Cerivastatin can be increased when it is combined with Mequitazine.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Cerivastatin.Experimental
MethadoneThe serum concentration of Cerivastatin can be increased when it is combined with Methadone.Approved
MethazolamideThe serum concentration of Cerivastatin can be increased when it is combined with Methazolamide.Approved
MethylergometrineThe serum concentration of Cerivastatin can be increased when it is combined with Methylergometrine.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Cerivastatin.Approved
MetoclopramideThe risk or severity of myopathy and rhabdomyolysis can be increased when Metoclopramide is combined with Cerivastatin.Approved, Investigational
MetronidazoleThe serum concentration of Cerivastatin can be increased when it is combined with Metronidazole.Approved
MetyraponeThe serum concentration of Cerivastatin can be increased when it is combined with Metyrapone.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Cerivastatin.Experimental
MibefradilThe metabolism of Cerivastatin can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Cerivastatin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Cerivastatin can be increased when it is combined with Midazolam.Approved, Illicit
MidecamycinThe risk or severity of rhabdomyolysis can be increased when Midecamycin is combined with Cerivastatin.Approved
MifepristoneThe serum concentration of Cerivastatin can be increased when it is combined with Mifepristone.Approved, Investigational
MiocamycinThe risk or severity of rhabdomyolysis can be increased when Miocamycin is combined with Cerivastatin.Experimental
MirtazapineThe serum concentration of Cerivastatin can be increased when it is combined with Mirtazapine.Approved
Mirvetuximab SoravtansineThe risk or severity of rhabdomyolysis can be increased when Mirvetuximab Soravtansine is combined with Cerivastatin.Investigational
MitemcinalThe risk or severity of rhabdomyolysis can be increased when Mitemcinal is combined with Cerivastatin.Investigational
MitotaneThe serum concentration of Cerivastatin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Cerivastatin can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Cerivastatin can be increased when it is combined with Modafinil.Approved, Investigational
NabiloneThe serum concentration of Cerivastatin can be increased when it is combined with Nabilone.Approved, Investigational
NatamycinThe risk or severity of rhabdomyolysis can be increased when Natamycin is combined with Cerivastatin.Approved
NefazodoneThe serum concentration of Cerivastatin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Cerivastatin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Cerivastatin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Cerivastatin can be increased when it is combined with Nevirapine.Approved
NiacinThe risk or severity of rhabdomyolysis can be increased when Niacin is combined with Cerivastatin.Approved, Investigational, Nutraceutical
NicardipineThe serum concentration of Cerivastatin can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Cerivastatin.Approved, Investigational
NicotinamideThe serum concentration of Cerivastatin can be increased when it is combined with Nicotinamide.Approved, Investigational
NifedipineThe excretion of Cerivastatin can be decreased when combined with Nifedipine.Approved
NiguldipineThe serum concentration of Cerivastatin can be increased when it is combined with Niguldipine.Experimental
NilotinibThe serum concentration of Cerivastatin can be increased when it is combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Cerivastatin can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Cerivastatin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Cerivastatin can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe serum concentration of Cerivastatin can be increased when it is combined with Nitric Oxide.Approved
NorfloxacinThe serum concentration of Cerivastatin can be increased when it is combined with Norfloxacin.Approved
NoscapineThe serum concentration of Cerivastatin can be increased when it is combined with Noscapine.Investigational
NystatinThe excretion of Cerivastatin can be decreased when combined with Nystatin.Approved, Vet Approved
OlanzapineThe serum concentration of Cerivastatin can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Cerivastatin can be increased when it is combined with Olaparib.Approved
OleandomycinThe risk or severity of rhabdomyolysis can be increased when Oleandomycin is combined with Cerivastatin.Vet Approved
OmeprazoleThe serum concentration of Cerivastatin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Cerivastatin can be increased when it is combined with Osimertinib.Approved
OxetacaineThe serum concentration of Cerivastatin can be increased when it is combined with Oxetacaine.Approved, Investigational
OxybutyninThe serum concentration of Cerivastatin can be increased when it is combined with Oxybutynin.Approved, Investigational
OxymetholoneThe serum concentration of Cerivastatin can be increased when it is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe serum concentration of Cerivastatin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Cerivastatin can be increased when it is combined with Palbociclib.Approved, Investigational
ParamethasoneThe serum concentration of Cerivastatin can be increased when it is combined with Paramethasone.Approved
ParoxetineThe serum concentration of Cerivastatin can be increased when it is combined with Paroxetine.Approved, Investigational
PatupiloneThe risk or severity of rhabdomyolysis can be increased when Patupilone is combined with Cerivastatin.Experimental, Investigational
PazopanibCerivastatin may increase the hepatotoxic activities of Pazopanib.Approved
PentobarbitalThe metabolism of Cerivastatin can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Peppermint oilThe serum concentration of Cerivastatin can be increased when it is combined with Peppermint oil.Approved, Investigational
PergolideThe serum concentration of Cerivastatin can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PhenelzineThe serum concentration of Cerivastatin can be increased when it is combined with Phenelzine.Approved
PhenobarbitalThe serum concentration of Cerivastatin can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenytoinThe serum concentration of Cerivastatin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Cerivastatin can be increased when it is combined with Pilocarpine.Approved, Investigational
PimecrolimusThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Cerivastatin.Approved, Investigational
PimozideThe serum concentration of Cerivastatin can be increased when it is combined with Pimozide.Approved
PioglitazoneThe metabolism of Cerivastatin can be decreased when combined with Pioglitazone.Approved, Investigational
PiperaquineThe serum concentration of Cerivastatin can be increased when it is combined with Piperaquine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cerivastatin.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Cerivastatin.Approved, Investigational
PosaconazoleThe serum concentration of Cerivastatin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cerivastatin.Approved
PrednisoneThe serum concentration of Cerivastatin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Cerivastatin can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Cerivastatin can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Cerivastatin can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Cerivastatin can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Cerivastatin can be increased when it is combined with Propafenone.Approved
PropofolThe serum concentration of Cerivastatin can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
QuinidineThe serum concentration of Cerivastatin can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Cerivastatin can be increased when it is combined with Quinine.Approved
QuinupristinThe serum concentration of Cerivastatin can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe serum concentration of Cerivastatin can be increased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe serum concentration of Cerivastatin can be increased when it is combined with Raloxifene.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Cerivastatin.Approved
RanitidineThe serum concentration of Cerivastatin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Cerivastatin can be increased when it is combined with Ranolazine.Approved, Investigational
RegorafenibThe serum concentration of Cerivastatin can be increased when it is combined with Regorafenib.Approved
RepaglinideThe serum concentration of Cerivastatin can be increased when it is combined with Repaglinide.Approved, Investigational
ResveratrolThe serum concentration of Cerivastatin can be increased when it is combined with Resveratrol.Approved, Experimental, Investigational
RidaforolimusThe risk or severity of rhabdomyolysis can be increased when Ridaforolimus is combined with Cerivastatin.Investigational
RifabutinThe metabolism of Cerivastatin can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Cerivastatin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Cerivastatin can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Cerivastatin can be decreased when it is combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Cerivastatin.Approved
RisperidoneThe serum concentration of Cerivastatin can be increased when it is combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Cerivastatin can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe serum concentration of Cerivastatin can be increased when it is combined with Rivastigmine.Approved, Investigational
RokitamycinThe risk or severity of rhabdomyolysis can be increased when Rokitamycin is combined with Cerivastatin.Experimental
RolapitantThe serum concentration of Cerivastatin can be increased when it is combined with Rolapitant.Approved, Investigational
RolitetracyclineThe serum concentration of Cerivastatin can be increased when it is combined with Rolitetracycline.Approved
RosiglitazoneThe metabolism of Cerivastatin can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Cerivastatin is combined with Rosuvastatin.Approved
RoxithromycinThe serum concentration of Cerivastatin can be increased when it is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Cerivastatin can be increased when it is combined with Rucaparib.Approved, Investigational
RutinThe serum concentration of Cerivastatin can be increased when it is combined with Rutin.Experimental, Investigational
SagopiloneThe risk or severity of rhabdomyolysis can be increased when Sagopilone is combined with Cerivastatin.Investigational
SalmeterolThe risk or severity of myopathy and rhabdomyolysis can be increased when Salmeterol is combined with Cerivastatin.Approved
SaquinavirThe serum concentration of Cerivastatin can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Cerivastatin can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalThe metabolism of Cerivastatin can be increased when combined with Secobarbital.Approved, Vet Approved
SelamectinThe risk or severity of rhabdomyolysis can be increased when Selamectin is combined with Cerivastatin.Vet Approved
SertralineThe serum concentration of Cerivastatin can be increased when it is combined with Sertraline.Approved
SildenafilThe serum concentration of Cerivastatin can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Cerivastatin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Cerivastatin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Cerivastatin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Cerivastatin can be increased when it is combined with Sirolimus.Approved, Investigational
SitaxentanThe serum concentration of Cerivastatin can be increased when it is combined with Sitaxentan.Approved, Investigational, Withdrawn
Sodium bicarbonateThe serum concentration of Cerivastatin can be decreased when it is combined with Sodium bicarbonate.Approved
SorafenibThe serum concentration of Cerivastatin can be increased when it is combined with Sorafenib.Approved, Investigational
SpiramycinThe risk or severity of rhabdomyolysis can be increased when Spiramycin is combined with Cerivastatin.Approved
St. John's WortThe metabolism of Cerivastatin can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Cerivastatin can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleThe serum concentration of Cerivastatin can be increased when it is combined with Sulfamethoxazole.Approved
SulfanilamideThe serum concentration of Cerivastatin can be increased when it is combined with Sulfanilamide.Approved
SulfasalazineThe serum concentration of Cerivastatin can be increased when it is combined with Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Cerivastatin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Cerivastatin can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Cerivastatin can be increased when it is combined with Tacrolimus.Approved, Investigational
TadalafilThe serum concentration of Cerivastatin can be increased when it is combined with Tadalafil.Approved, Investigational
TamoxifenThe serum concentration of Cerivastatin can be increased when it is combined with Tamoxifen.Approved
TelaprevirThe serum concentration of Cerivastatin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe risk or severity of rhabdomyolysis can be increased when Telithromycin is combined with Cerivastatin.Approved
TemsirolimusThe serum concentration of Cerivastatin can be increased when it is combined with Temsirolimus.Approved
TeniposideThe serum concentration of Cerivastatin can be increased when it is combined with Teniposide.Approved
TerbinafineThe risk or severity of myopathy and rhabdomyolysis can be increased when Terbinafine is combined with Cerivastatin.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Cerivastatin can be increased when it is combined with Terfenadine.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Cerivastatin.Experimental
TeriflunomideThe serum concentration of Cerivastatin can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Cerivastatin can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Cerivastatin can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Cerivastatin can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Cerivastatin can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Cerivastatin can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetrandrineThe serum concentration of Cerivastatin can be increased when it is combined with Tetrandrine.Experimental
ThiopentalThe serum concentration of Cerivastatin can be increased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Cerivastatin.Approved, Withdrawn
TicagrelorThe serum concentration of Cerivastatin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Cerivastatin can be increased when it is combined with Ticlopidine.Approved
TildipirosinThe risk or severity of rhabdomyolysis can be increased when Tildipirosin is combined with Cerivastatin.Vet Approved
TilmicosinThe risk or severity of rhabdomyolysis can be increased when Tilmicosin is combined with Cerivastatin.Investigational, Vet Approved
TipranavirThe serum concentration of Cerivastatin can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Cerivastatin can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe serum concentration of Cerivastatin can be increased when it is combined with Tofisopam.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cerivastatin.Approved
TopiroxostatThe serum concentration of Cerivastatin can be increased when it is combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Cerivastatin can be increased when it is combined with Topotecan.Approved, Investigational
TrabectedinCerivastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TranylcypromineThe serum concentration of Cerivastatin can be increased when it is combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe risk or severity of rhabdomyolysis can be increased when Trastuzumab emtansine is combined with Cerivastatin.Approved, Investigational
TrimethoprimThe metabolism of Cerivastatin can be decreased when combined with Trimethoprim.Approved, Vet Approved
TroglitazoneThe serum concentration of Cerivastatin can be increased when it is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe serum concentration of Cerivastatin can be increased when it is combined with Troleandomycin.Approved
TromethamineThe serum concentration of Cerivastatin can be decreased when it is combined with Tromethamine.Approved
TylosinThe risk or severity of rhabdomyolysis can be increased when Tylosin is combined with Cerivastatin.Vet Approved
TylvalosinThe risk or severity of rhabdomyolysis can be increased when Tylvalosin is combined with Cerivastatin.Vet Approved
VemurafenibThe serum concentration of Cerivastatin can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Cerivastatin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Cerivastatin can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Cerivastatin can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Cerivastatin can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Cerivastatin can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of Cerivastatin can be increased when it is combined with Voriconazole.Approved, Investigational
ZafirlukastThe serum concentration of Cerivastatin can be increased when it is combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Cerivastatin can be decreased when it is combined with Zidovudine.Approved
ZiprasidoneThe serum concentration of Cerivastatin can be increased when it is combined with Ziprasidone.Approved
ZucapsaicinThe serum concentration of Cerivastatin can be increased when it is combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly increase serum levels of this product.
  • Take without regard to meals.

References

General References
  1. Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2(5):205-207. [PubMed:11806796]
External Links
KEGG Compound
C07966
PubChem Compound
446156
PubChem Substance
46505877
ChemSpider
393588
BindingDB
18376
ChEBI
3558
ChEMBL
CHEMBL1477
Therapeutic Targets Database
DNC000403
PharmGKB
PA448897
HET
116
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cerivastatin
ATC Codes
C10AA06 — Cerivastatin
FDA label
Download (144 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Bayer pharmaceuticals corp
Packagers
  • Bayer Healthcare
Dosage forms
FormRouteStrength
TabletOral0.4 mg
TabletOral0.8 mg
TabletOral0.2 mg
TabletOral0.3 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5177080No1994-11-262011-11-26Us
CA1340798No1999-10-262016-10-26Canada
CA2057444No1998-05-262011-12-11Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityHighly solubilityNot Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00419 mg/mLALOGPS
logP4.15ALOGPS
logP2.67ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)4.05ChemAxon
pKa (Strongest Basic)5.58ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area99.88 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity126.82 m3·mol-1ChemAxon
Polarizability50.23 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9628
Blood Brain Barrier+0.9381
Caco-2 permeable+0.5141
P-glycoprotein substrateSubstrate0.6231
P-glycoprotein inhibitor INon-inhibitor0.5221
P-glycoprotein inhibitor IINon-inhibitor0.719
Renal organic cation transporterNon-inhibitor0.8848
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.672
CYP450 1A2 substrateNon-inhibitor0.67
CYP450 2C9 inhibitorNon-inhibitor0.64
CYP450 2D6 inhibitorNon-inhibitor0.8717
CYP450 2C19 inhibitorNon-inhibitor0.596
CYP450 3A4 inhibitorNon-inhibitor0.6191
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5668
Ames testNon AMES toxic0.817
CarcinogenicityNon-carcinogens0.8706
BiodegradationNot ready biodegradable0.9881
Rat acute toxicity2.6748 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9901
hERG inhibition (predictor II)Non-inhibitor0.8623
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Phenylpyridines
Direct Parent
Phenylpyridines
Alternative Parents
Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Hydroxy fatty acids / Heterocyclic fatty acids / Halogenated fatty acids / Fluorobenzenes / Unsaturated fatty acids / Aryl fluorides / Heteroaromatic compounds
show 11 more
Substituents
4-phenylpyridine / Medium-chain hydroxy acid / Medium-chain fatty acid / Hydroxy fatty acid / Heterocyclic fatty acid / Beta-hydroxy acid / Fluorobenzene / Halogenated fatty acid / Halobenzene / Aryl fluoride
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
statin (synthetic), pyridines, dihydroxy monocarboxylic acid (CHEBI:3558)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Shiomi M, Ito T: Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol. 1999 Feb;126(4):961-8. [PubMed:10193776]
  2. Blumenthal RS: Statins: effective antiatherosclerotic therapy. Am Heart J. 2000 Apr;139(4):577-83. [PubMed:10740137]
  3. Ganne F, Vasse M, Beaudeux JL, Peynet J, Francois A, Mishal Z, Chartier A, Tobelem G, Vannier JP, Soria J, Soria C: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis. Thromb Haemost. 2000 Oct;84(4):680-8. [PubMed:11057870]
  4. Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ: Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res. 2001 Jul;7(7):2067-75. [PubMed:11448925]
  5. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001 Aug;22(8):1139-48. [PubMed:11470741]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. [PubMed:17178259]
  2. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M: Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos. 1997 Mar;25(3):321-31. [PubMed:9172950]
  6. Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ: Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 2002 Dec;30(12):1352-6. [PubMed:12433802]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. [PubMed:17178259]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ: Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 2002 Dec;30(12):1352-6. [PubMed:12433802]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Dancygier H. (2010). Clinical Hepatology. Springer-Verlag. [ISBN:978-3-642-04509-7]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
  2. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799]
  3. Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, Ma B, Chu C, Marciante KD, Heckbert SR, Psaty BM, Kroetz DL, Kwok PY: OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics. 2013 Jul;23(7):355-64. doi: 10.1097/FPC.0b013e3283620c3b. [PubMed:23652407]
  4. Karlgren M, Ahlin G, Bergstrom CA, Svensson R, Palm J, Artursson P: In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res. 2012 Feb;29(2):411-26. doi: 10.1007/s11095-011-0564-9. Epub 2011 Aug 23. [PubMed:21861202]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:40